Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnold Lee

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Molecular Diagnosis & Therapy|January 31, 2025
Obecabtagene Autoleucel: First ApprovalArnold Lee
Molecular Diagnosis & Therapy|November 8, 2025
Zopapogene Imadenovec: First ApprovalArnold Lee
Drugs|July 27, 2021
Ibrexafungerp: First ApprovalArnold Lee
Drugs|July 18, 2023
Fezolinetant: First ApprovalArnold Lee
Targeted Oncology|October 31, 2022
Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung CancerArnold Lee
Drugs|June 18, 2020
Tucatinib: First ApprovalArnold Lee
Drugs|April 1, 2022
Clazosentan: First ApprovalArnold Lee
Drugs|March 26, 2026
Depemokimab: First ApprovalArnold Lee
Drugs|April 7, 2026
Tradipitant: First ApprovalArnold Lee
Drugs|March 15, 2023
Ublituximab: First ApprovalArnold Lee
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Molecular Diagnosis & Therapy|January 31, 2025
Obecabtagene Autoleucel: First ApprovalArnold Lee
Molecular Diagnosis & Therapy|November 8, 2025
Zopapogene Imadenovec: First ApprovalArnold Lee
Drugs|July 27, 2021
Ibrexafungerp: First ApprovalArnold Lee
Drugs|July 18, 2023
Fezolinetant: First ApprovalArnold Lee
Targeted Oncology|October 31, 2022
Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung CancerArnold Lee
Drugs|June 18, 2020
Tucatinib: First ApprovalArnold Lee
Drugs|April 1, 2022
Clazosentan: First ApprovalArnold Lee
Drugs|March 26, 2026
Depemokimab: First ApprovalArnold Lee
Drugs|April 7, 2026
Tradipitant: First ApprovalArnold Lee
Drugs|March 15, 2023
Ublituximab: First ApprovalArnold Lee
Pageof 10